Featured Content

Winston Wong, PharmD
President, W-Squared Group

Examining the Rising Costs of Cancer Care

(WGGB-TV/ABC, Ch. 40 [Springfield, MA]) Nov 20, 2014 - It’s a grim reality and a dire decision facing thousands of cancer patients, even those with health insurance: the costs of treating cancer have skyrocketed and many sufferers can’t afford to stay alive.

Commentary: The fundamental points made here are accurate. The discrepancy between cost in the US vs. everywhere else goes...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Novartis Announces Extension to FDA Review Period For Multiple Myeloma Investigational Compound LBH589

(Novartis) Nov 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (NDA) of LBH589 (panobinostat) in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma.
read corporate press release »

Roche's Genentech Defends Supply Shift For Top Cancer Drugs

(Reuters) Nov 24, 2014 - Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will create delays and raise costs.
read article »

New Drugs Treat Advanced Stages of a Common Skin Cancer

(Wall Street Journal) Nov 24, 2014 – The incidence of melanoma has been rising for at least 30 years, according to the American Academy of Dermatology, and several new drugs in recent years have improved survival rates in advanced cases.
read article (paid subscription required) »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Examining the Rising Costs of Cancer Care (WGGB-TV/ABC, Ch. 40 [Springfield, MA])

The fundamental points made here are accurate. The discrepancy between cost in the US vs. everywhere else goes...posted by: Winston Wong, PharmD

ASCO Takes Part in IOM Workshop on Molecularly Targeted Therapies for Cancer (ASCO in Action)

Hopefully this will help promote the molecular profiling space, and help payers gain confidence that these test...posted by: Winston Wong, PharmD

Cost to Develop a Drug More Than Doubles to $2.56 Billion (Bloomberg)

At the end of the day, transparency is the key to all of us understanding the cost of development, and what is...posted by: Winston Wong, PharmD

Payers Evaluate the Clinical Utility of Diagnostic Tests (AJMC.com)

The question that payers need answered with regards to covering molecular profiling test are really 2-fold. First,...posted by: Winston Wong, PharmD

Transplant Best For HIV Patients With Liver Cancer (MedPage Today)

The only concern that would remain is if the patient had Hep C.posted by: Winston Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

NCCN has posted 1 new job.

Bayer Biopharmaceuticals, Inc. has posted 20 jobs.

Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.

View OBR Job Board>>


The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
IDRA +8.11%
NKTR +6.34%
CRIS +5.15%
PARD -25.00%
GERN -6.51%
FATE -5.76%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: December 5, 2014
Company: Novartis / Incyte Corp.
Product: Jakafi® (ruxolitinib)

Date: January 3, 2015
Company: AstraZeneca PLC
Product: Olaparib

Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

See All OBR Radar items»